scholarly journals Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Krishnankutty Sudhir ◽  
James B. Hermiller ◽  
Joanne M. Ferguson ◽  
Charles A. Simonton
Keyword(s):  
Risk Factors ◽  
Stent Thrombosis ◽  
Large Scale ◽  
First Generation ◽  
Randomized Clinical Trials ◽  
Antiplatelet Agents ◽  
Drug Eluting Stent ◽  
Related Factors ◽  
Vasomotor Function ◽  
Drug Eluting

The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. The optimal duration of DAPT for DES is currently unclear and will be addressed in large-scale randomized clinical trials.

scholarly journals Risk Factors and Outcomes of Recurrent Drug‐Eluting Stent Thrombosis: Insights From the REAL‐ST Registry

2021 ◽  
Vol 10 (9) ◽  
Author(s):  
Soichiro Enomoto ◽  
Shoichi Kuramitsu ◽  
Tomohiro Shinozaki ◽  
Masanobu Ohya ◽  
Hiromasa Otake ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stent Thrombosis ◽  
Cumulative Incidence ◽  
First Generation ◽  
Second Generation ◽  
Clinical Importance ◽  
Drug Eluting Stent ◽  
Unique Identifier ◽  
Increased Risk ◽  
Drug Eluting

Background Stent thrombosis (ST) after drug‐eluting stent (DES) implantation remains a life‐threatening complication. Recurrent ST (RST) is not a rare phenomenon, potentially contributing to high mortality after the index ST events. However, little evidence is available about the incidence, risk factors, and clinical outcomes of definite RST after DES thrombosis. Methods and Results From REAL‐ST (Retrospective Multicenter Registry of ST After First‐ and Second‐ Generation DES Implantation), this study evaluated 595 patients with definite ST (first‐generation DES thrombosis, n=314; second‐generation DES thrombosis, n=281). During a median follow‐up of 31 months, we identified 32 patients with definite RST after first‐generation DES thrombosis (n=18) and second‐generation DES thrombosis (n=15). Cumulative incidence of RST was 4.5% and 6.0% at 1 and 5 years, respectively, which did not significantly differ between first‐generation DES thrombosis and second‐generation DES thrombosis. Independent predictors of definite RST were early ST (hazard ratio [HR], 2.38; 95% CI, 1.06–5.35 [ P =0.035]) and multivessel ST (HR, 3.47; 95% CI, 1.03–11.7 [ P =0.044]). Definite RST was associated with a 2.8‐fold increased risk of mortality (adjusted HR, 2.78; 95% CI, 1.35–5.73 [ P =0.006]). Conclusions Cumulative incidence of definite RST did not significantly differ between first‐generation DES thrombosis and second‐generation DES thrombosis. Early ST and multivessel ST were risk factors of definite RST. Definite RST significantly increased mortality after DES thrombosis, highlighting the clinical importance of preventing RST to improve outcomes of patients with ST. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: UMIN000025181.

scholarly journals Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis

2019 ◽  
Vol 12 (6) ◽  
Author(s):  
Shoichi Kuramitsu ◽  
Masanobu Ohya ◽  
Tomohiro Shinozaki ◽  
Hiromasa Otake ◽  
Kazunori Horie ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Outcomes ◽  
Stent Thrombosis ◽  
Second Generation ◽  
Drug Eluting Stent ◽  
Drug Eluting

scholarly journals Histopathologically confirmed very late stent thrombosis associated with stent fracture after implantation of first-generation drug eluting stent

2020 ◽  
Vol 27 (2) ◽  
pp. 204-205
Author(s):  
Takao Konishi ◽  
Naohiro Funayama ◽  
Tadashi Yamamoto ◽  
Daisuke Hotta ◽  
Yuta Kobayashi ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
First Generation ◽  
Drug Eluting Stent ◽  
Stent Fracture ◽  
Late Stent Thrombosis ◽  
Very Late Stent Thrombosis ◽  
Drug Eluting

scholarly journals Extremely Late Stent Thrombosis in a First Generation Drug- Eluting Stent 10 Years After Stent Deployment: A Case Report

2021 ◽  
Vol 36 (2) ◽  
pp. 164-168
Author(s):  
Fazila Tun Nesa Malik ◽  
- Md Kalimuddin ◽  
Nazir Ahmed ◽  
Mohammad Badiuzzaman
Keyword(s):  
Case Report ◽  
Stent Thrombosis ◽  
First Generation ◽  
Case Reports ◽  
Drug Eluting Stent ◽  
Late Stent Thrombosis ◽  
Stent Deployment ◽  
St Segment Elevation ◽  
First Case ◽  
Drug Eluting

Stent thrombosis is one of the gravest complications of percutaneous coronary intervention which usually manifest as ST-segment elevation myocardial infarction or sudden death. There are a very few case reports in the literature regarding extremely late stent thrombosis in a drug-eluting stent. Here we report a case of extremely late stent thrombosis in a first generation drug-eluting stent in a 54 year old gentleman. To the best of our knowledge, this is the first case report with the longest duration (10 years) after sirolimus eluting first-generation DES in Bangladesh. Bangladesh Heart Journal 2021; 36(2): 164-168

scholarly journals Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial

2015 ◽  
Vol 34 (3) ◽  
pp. 193-199 ◽  
Author(s):  
Eduardo Arroyo-Úcar ◽  
Raul Moreno ◽  
Eulogio García ◽  
Rui Teles ◽  
Jose-Ramon Rumoroso ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
Drug Eluting Stent ◽  
Related Factors ◽  
Drug Eluting ◽  
Total Coronary Occlusions

Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-Up

2006 ◽  
Vol 98 (3) ◽  
pp. 352-356 ◽  
Author(s):  
Duk-Woo Park ◽  
Seong-Wook Park ◽  
Kyoung-Ha Park ◽  
Bong-Ki Lee ◽  
Young-Hak Kim ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stent Thrombosis ◽  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Long Term Follow Up ◽  
Drug Eluting

scholarly journals Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder

2015 ◽  
Vol 42 (5) ◽  
pp. 483-486 ◽  
Author(s):  
Yi-Sik Kim ◽  
Sang-Rok Lee
Keyword(s):  
Stent Thrombosis ◽  
Stent Implantation ◽  
Potential Role ◽  
Poor Response ◽  
Antiplatelet Agents ◽  
Drug Eluting Stent ◽  
Variable Response ◽  
Life Threatening ◽  
Drug Eluting

Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual antiplatelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel, and this has raised interest in new antiplatelet agents. We present the case of a 64-year-old woman whom we successfully treated with prasugrel after she had repeated episodes of stent thrombosis caused by a poor response to clopidogrel. This case highlights the potential role of new antiplatelet agents for patients who are undergoing drug-eluting stent implantation.

Sign in / Sign up

Export Citation Format

Share Document